Tue. 14 May 2024, 7:33am ET
Benzinga
Earnings, Earnings Beats, News
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year.